{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T01:58:24Z","timestamp":1772848704623,"version":"3.50.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T00:00:00Z","timestamp":1766448000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T00:00:00Z","timestamp":1766448000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1038\/s41409-025-02765-1","type":"journal-article","created":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T07:37:18Z","timestamp":1766475438000},"page":"326-332","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The impact of DNMT3A mutation on survival of AML patients receiving allotransplant in first remission depends on the karyotype and co-occurring mutations"],"prefix":"10.1038","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6520-9134","authenticated-orcid":false,"given":"Iman","family":"Abou Dalle","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9102-4427","authenticated-orcid":false,"given":"Jacques-Emmanuel","family":"Galimard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1897-0227","authenticated-orcid":false,"given":"Xavier","family":"Poire","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6934-4619","authenticated-orcid":false,"given":"Jaime","family":"Sanz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Huynh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolaus","family":"Kr\u00f6ger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0728-2253","authenticated-orcid":false,"given":"Eva Maria","family":"Wagner-Drouet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Burns","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Eder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Lioure","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Depei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiri","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristina","family":"Carlson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9331-5145","authenticated-orcid":false,"given":"Matthias","family":"Stelljes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Collin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahmoud","family":"Aljurf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arnon","family":"Nagler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8056-648X","authenticated-orcid":false,"given":"Jordi","family":"Esteve","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabio","family":"Ciceri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7171-4997","authenticated-orcid":false,"given":"Ali","family":"Bazarbachi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7264-808X","authenticated-orcid":false,"given":"Mohamad","family":"Mohty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,23]]},"reference":[{"key":"2765_CR1","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1182\/blood-2016-01-693879","volume":"128","author":"KH Metzeler","year":"2016","unstructured":"Metzeler KH, Herold T, Rothenberg-Thurley M, Amler S, Sauerland MC, G\u00f6rlich D, et al. Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia. Blood. 2016;128:686\u201398. https:\/\/doi.org\/10.1182\/blood-2016-01-693879.","journal-title":"Blood"},{"key":"2765_CR2","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1182\/blood-2017-04-777029","volume":"130","author":"M Buscarlet","year":"2017","unstructured":"Buscarlet M, Provost S, Zada YF, Barhdadi A, Bourgoin V, L\u00e9pine G, et al. DNMT3A and TET2 dominate clonal hematopoiesis and demonstrate benign phenotypes and different genetic predispositions. Blood. 2017;130:753\u201362. https:\/\/doi.org\/10.1182\/blood-2017-04-777029.","journal-title":"Blood"},{"key":"2765_CR3","doi-asserted-by":"publisher","unstructured":"Jaiswal S, Ebert BL Clonal hematopoiesis in human aging and disease. Science (New York, N.Y.). 2019; 366. https:\/\/doi.org\/10.1126\/science.aan4673","DOI":"10.1126\/science.aan4673"},{"key":"2765_CR4","doi-asserted-by":"publisher","first-page":"2741","DOI":"10.1038\/s41375-019-0502-0","volume":"33","author":"LV Cappelli","year":"2019","unstructured":"Cappelli LV, Meggendorfer M, Dicker F, Jeromin S, Hutter S, Kern W, et al. DNMT3A mutations are over-represented in young adults with NPM1 mutated AML and prompt a distinct co-mutational pattern. Leukemia. 2019;33:2741\u20136. https:\/\/doi.org\/10.1038\/s41375-019-0502-0.","journal-title":"Leukemia"},{"key":"2765_CR5","doi-asserted-by":"publisher","first-page":"2424","DOI":"10.1056\/NEJMoa1005143","volume":"363","author":"TJ Ley","year":"2010","unstructured":"Ley TJ, Ding L, Walter MJ, McLellan MD, Lamprecht T, Larson DE, et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med. 2010;363:2424\u201333. https:\/\/doi.org\/10.1056\/NEJMoa1005143.","journal-title":"N Engl J Med"},{"key":"2765_CR6","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1200\/jco.2011.39.2092","volume":"30","author":"G Marcucci","year":"2012","unstructured":"Marcucci G, Metzeler KH, Schwind S, Becker H, Maharry K, Mr\u00f3zek K, et al. Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia. J Clin Oncol. 2012;30:742\u201350. https:\/\/doi.org\/10.1200\/jco.2011.39.2092.","journal-title":"J Clin Oncol"},{"key":"2765_CR7","doi-asserted-by":"publisher","first-page":"4769","DOI":"10.1182\/blood-2012-10-461624","volume":"121","author":"VI Gaidzik","year":"2013","unstructured":"Gaidzik VI, Schlenk RF, Paschka P, St\u00f6lzle A, Sp\u00e4th D, Kuendgen A, et al. Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AMLSG). Blood. 2013;121:4769\u201377. https:\/\/doi.org\/10.1182\/blood-2012-10-461624.","journal-title":"Blood"},{"key":"2765_CR8","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","volume":"374","author":"E Papaemmanuil","year":"2016","unstructured":"Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374:2209\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1516192.","journal-title":"N Engl J Med"},{"key":"2765_CR9","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1002\/ajh.25517","volume":"94","author":"JB Dunlap","year":"2019","unstructured":"Dunlap JB, Leonard J, Rosenberg M, Cook R, Press R, Fan G, et al. The combination of NPM1, DNMT3A, and IDH1\/2 mutations leads to inferior overall survival in AML. Am J Hematol. 2019;94:913\u201320. https:\/\/doi.org\/10.1002\/ajh.25517.","journal-title":"Am J Hematol"},{"key":"2765_CR10","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1182\/blood.2019003339","volume":"135","author":"MF Bezerra","year":"2020","unstructured":"Bezerra MF, Lima AS, Piqu\u00e9-Borr\u00e0s MR, Silveira DR, Coelho-Silva JL, Pereira-Martins DA, et al. Co-occurrence of DNMT3A, NPM1, FLT3 mutations identifies a subset of acute myeloid leukemia with adverse prognosis. Blood. 2020;135:870\u20135. https:\/\/doi.org\/10.1182\/blood.2019003339.","journal-title":"Blood"},{"key":"2765_CR11","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140:1345\u201377. https:\/\/doi.org\/10.1182\/blood.2022016867.","journal-title":"Blood"},{"key":"2765_CR12","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1182\/bloodadvances.2021004367","volume":"5","author":"M Heuser","year":"2021","unstructured":"Heuser M, Heida B, B\u00fcttner K, Wienecke CP, Teich K, Funke C, et al. Posttransplantation MRD monitoring in patients with AML by next-generation sequencing using DTA and non-DTA mutations. Blood Adv. 2021;5:2294\u2013304. https:\/\/doi.org\/10.1182\/bloodadvances.2021004367.","journal-title":"Blood Adv"},{"key":"2765_CR13","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s13045-014-0074-4","volume":"7","author":"S Loghavi","year":"2014","unstructured":"Loghavi S, Zuo Z, Ravandi F, Kantarjian HM, Bueso-Ramos C, Zhang L, et al. Clinical features of de novo acute myeloid leukemia with concurrent DNMT3A, FLT3 and NPM1 mutations. J Hematol Oncol. 2014;7:74. https:\/\/doi.org\/10.1186\/s13045-014-0074-4.","journal-title":"J Hematol Oncol"},{"key":"2765_CR14","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1038\/s41409-022-01762-y","volume":"57","author":"S Hong","year":"2022","unstructured":"Hong S, Rybicki L, Gurnari C, Pagliuca S, Zhang A, Thomas D, et al. Pattern of somatic mutation changes after allogeneic hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes. Bone Marrow Transpl. 2022;57:1615\u20139. https:\/\/doi.org\/10.1038\/s41409-022-01762-y.","journal-title":"Bone Marrow Transpl"},{"key":"2765_CR15","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1016\/j.bbmt.2016.07.018","volume":"22","author":"MR Luskin","year":"2016","unstructured":"Luskin MR, Carroll M, Lieberman D, Morrissette JJD, Zhao J, Crisalli L, et al. Clinical Utility of Next-Generation Sequencing for Oncogenic Mutations in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation. Biol Blood Marrow Transpl. 2016;22:1961\u20137. https:\/\/doi.org\/10.1016\/j.bbmt.2016.07.018.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2765_CR16","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.bbmt.2015.07.030","volume":"22","author":"JS Ahn","year":"2016","unstructured":"Ahn JS, Kim HJ, Kim YK, Lee SS, Jung SH, Yang DH, et al. DNMT3A R882 mutation with FLT3-ITD positivity is an extremely poor prognostic factor in patients with normal-karyotype acute myeloid leukemia after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transpl. 2016;22:61\u201370. https:\/\/doi.org\/10.1016\/j.bbmt.2015.07.030.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2765_CR17","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.exphem.2020.09.192","volume":"91","author":"J Chen","year":"2020","unstructured":"Chen J, Matatall KA, Feng X, Hormaechea-Agulla D, Maharjan M, Young N, et al. Dnmt3a-null hematopoietic stem and progenitor cells expand after busulfan treatment. Exp Hematol. 2020;91:39\u201345.e32. https:\/\/doi.org\/10.1016\/j.exphem.2020.09.192.","journal-title":"Exp Hematol"},{"key":"2765_CR18","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1182\/bloodadvances.2016000760","volume":"1","author":"L Quek","year":"2016","unstructured":"Quek L, Ferguson P, Metzner M, Ahmed I, Kennedy A, Garnett C, et al. Mutational analysis of disease relapse in patients allografted for acute myeloid leukemia. Blood Adv. 2016;1:193\u2013204. https:\/\/doi.org\/10.1182\/bloodadvances.2016000760.","journal-title":"Blood Adv"},{"key":"2765_CR19","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1007\/s11864-024-01202-7","volume":"25","author":"M Tecik","year":"2024","unstructured":"Tecik M, Adan A. Emerging DNA methylome targets in FLT3-ITD-positive acute myeloid leukemia: combination therapy with clinically approved FLT3 inhibitors. Curr Treat options Oncol. 2024;25:719\u201351. https:\/\/doi.org\/10.1007\/s11864-024-01202-7.","journal-title":"Curr Treat options Oncol"},{"key":"2765_CR20","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1111\/cas.15720","volume":"114","author":"S Wakita","year":"2023","unstructured":"Wakita S, Marumo A, Morita K, Kako S, Toya T, Najima Y, et al. Mutational analysis of DNMT3A improves the prognostic stratification of patients with acute myeloid leukemia. Cancer Sci. 2023;114:1297\u2013308. https:\/\/doi.org\/10.1111\/cas.15720.","journal-title":"Cancer Sci"},{"key":"2765_CR21","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1182\/blood.2024024310","volume":"144","author":"J Othman","year":"2024","unstructured":"Othman J, Potter N, Ivey A, Tazi Y, Papaemmanuil E, Jovanovic J, et al. Molecular, clinical, and therapeutic determinants of outcome in NPM1-mutated AML. Blood. 2024;144:714\u201328. https:\/\/doi.org\/10.1182\/blood.2024024310.","journal-title":"Blood"},{"key":"2765_CR22","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1182\/bloodadvances.2020004136","volume":"6","author":"G O\u00f1ate","year":"2022","unstructured":"O\u00f1ate G, Bataller A, Garrido A, Hoyos M, Arnan M, Vives S, et al. Prognostic impact of DNMT3A mutation in acute myeloid leukemia with mutated NPM1. Blood Adv. 2022;6:882\u201390. https:\/\/doi.org\/10.1182\/bloodadvances.2020004136.","journal-title":"Blood Adv"},{"key":"2765_CR23","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1080\/10428194.2023.2284089","volume":"65","author":"X Lai","year":"2024","unstructured":"Lai X, Xiao J, Wang T, Hou C, Chen J, Wu D, et al. Prognostic significance of persisting DNMT3A, ASXL1, and TET2 mutation burden in acute myeloid leukemia patients with allogeneic hematopoietic stem cell transplantation during complete remission. Leuk lymphoma. 2024;65:363\u201371. https:\/\/doi.org\/10.1080\/10428194.2023.2284089.","journal-title":"Leuk lymphoma"},{"key":"2765_CR24","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1182\/blood.2018862383","volume":"134","author":"S Garg","year":"2019","unstructured":"Garg S, Reyes-Palomares A, He L, Bergeron A, Lavall\u00e9e VP, Lemieux S, et al. Hepatic leukemia factor is a novel leukemic stem cell regulator in DNMT3A, NPM1, and FLT3-ITD triple-mutated AML. Blood. 2019;134:263\u201376. https:\/\/doi.org\/10.1182\/blood.2018862383.","journal-title":"Blood"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02765-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02765-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02765-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T14:56:07Z","timestamp":1772808967000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02765-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,23]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["2765"],"URL":"https:\/\/doi.org\/10.1038\/s41409-025-02765-1","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,23]]},"assertion":[{"value":"25 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The EBMT is a voluntary working group of more than 600 transplant centers that are required to report all consecutive HCTs and follow-ups once a year. Audits are routinely performed to determine the accuracy of the data. Since January 2003, all transplant centers have been required to obtain written informed consent before data registration with the EBMT, following the guidelines of the Declaration of Helsinki, 1975.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}